Warning for J&J and AZ COVID Vaccines: Guillain-Barre syndrome
September 1, 2021 (1)
Medical regulators from European Medicines Agency (EMA) advised health
care professionals to be on the lookout for cases of Guillain-Barre
syndrome (GBS) with Johnson & Johnson’s and AstraZenca’s COVID
GBS is a rare but serious condition in which the immune system starts
attacking the body’s healthy nerve cells, resulting in pain, numbness
and muscle weakness in extremities that can also spread to the chest
and face. While the EMA stops short of saying there is a causal
relationship, they are advising people to seek immediate medical
attention if they develop weakness and paralysis following a COVID
According to the report, most adults in the U.K. are already
vaccinated, which is why early recognition of post-vaccine autoimmune
conditions like GBS are important for developing early therapeutic
Of the 335 million doses of the J&J single dose vaccine
administered globally, only 13 million were administered in the U.S.
Those 13 million doses were followed by 100 reports of
Guillain-Barré syndrome, according to the FDA, in which one
person died and 95 were hospitalized. “Men aged over 50 showed the
greatest risk, and cases typically appeared about two weeks after
vaccination,” according to the BMJ.
Report, 1-Sep-2021 (only available in the original site for 48
hours after publication date)
(2) Sources as quoted in the
original News Report page:
© Copyright by Dr. Joseph Mercola.
However, since August 2021 he declared: "Again
I will still be writing my daily articles that I started 25 years ago
BUT they will only be available for 48 hours before they are removed.
In this way I hope to continue my mission to help you take control of
your health – but it's up to you to download, share and repost this
content. I will not be enforcing my
copyright on this information so that you may freely share it."